CO2 Laser Matrixectomy for Refractory MEK Inhibitor-Induced Paronychia in Children: A Case Series.

Paronychia is a frequent cutaneous adverse event associated with MEK inhibitor therapy and may significantly impair quality of life and compromise treatment adherence. Treatment is usually medical, with poor and unsustained results. We retrospectively evaluated the safety and efficacy of CO2 laser matrixectomy in children at a tertiary center between 2016 and 2026. Five patients with prolonged symptoms despite multiple conservative treatments were identified. Complete resolution was achieved in all patients, with no procedure-related complications. MEK inhibitor therapy was continued without recurrence of paronychia. Outcomes remained favorable during a mean follow-up of 4 years.